Ironwood Pharmaceuticals Announces FDA Approval of New Indication for Linzess (linaclotide) for the Treatment of Functional Constipation in Pediatric Patients Ages 6-17 Years-Old

BOSTON--(BUSINESS WIRE) June 12, 2023 -- Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has approved Linzess® (linaclotide) as a once-daily...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news